Marco Bua

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

David Marín, Alexandra Bazeos, François-Xavier Mahon et al. · Journal of Clinical Oncology · 2010 · 901 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

Hugues de Lavallade, Jane F. Apperley, Jamshid S. Khorashad et al. · Journal of Clinical Oncology · 2008 · 556 citations

Medicine, Hematology, Pharmacology +8

Assessment of <i>BCR-ABL1</i> Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

David Marín, Amr R. Ibrahim, Claire Lucas et al. · Journal of Clinical Oncology · 2011 · 475 citations

Medicine, Hematology, Oncology +13

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

David Marín, Dragana Milojković, Eduardo Olavarría et al. · Blood · 2008 · 328 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

Amr R. Ibrahim, Lina Eliasson, Jane F. Apperley et al. · Blood · 2011 · 316 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +7